Lisa M. Rimsza, MD

Professor of Pathology

E-Mail Address: 
Phone Number: 
(520)626-8396
Fax: 
(520)626-6081
Short Bio: 

Dr. Rimsza works as a diagnostic Hematopathologist, is the Director of Flow Cytometry, and the Directory of the Molecular Genetic Pathology Fellowship at the University of Arizona Medical Center.

Dr. Rimsza received her medical degree from the University of Arizona in Tucson.  She completed Anatomic and Clinical Pathology residency training at the University of Arizona and her two-year fellowship in Hematopathology at the University of New Mexico in Albuquerque.

Clinical Information
Specialty: 
Pathologist
Research Information
Research Program: 
1. Therapeutic Development
Member Status: 
Member
Summary of Research Activity: 

As a long term member and current principal investigator of the international collaborative group, the Leukemia and Lymphoma Molecular Profiling Project, Dr. Rimsza is involved with development of new molecular methods, including gene expression profiling in frozen and paraffin embedded tissues, for lymphoma diagnosis and prognosis. She also directs the Arizona Lymphoid Tissue and Blood Repository and collaborates with the biotech industry on new test development. Dr. Rimsza is currently the Chair of the Southwest Oncology Lymphoma Translational Medicine Subcommittee, working closely with the lymphoma physicians on new treatment strategies for patients. Her primary research focuses on the biology of diffuse large B cell lymphoma, particularly the investigation of prognostic biomarkers and mechanisms of lost tumor immunosurveillance. She also has collaborative research projects in the field of neonatal thrombocytopenia.

Selected Publications: 

1. Rimsza LM, Roberts RA, Campo E, Grogan TM, Bea S, Salaverria I, Zettl A, Rosenwald A, Ott G, Muller-Hermelink HK, Delabie J, Fisher RI, Unger JM, LeBlanc M, Staudt LM, Jaffe ES, Gascoyne RD, Chan WC, Weisenburger DD, Greiner T, Braziel RM, Miller TP. Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood 2006;107:1101-1107. PMCID: PMC1895840
2. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project. Molecular diagnosis of Burkitt's lymphoma, N Engl J Med 2006;354:2431-2442.
3. Roberts RA, Wright G, Rosenwald AR, Jaramillo MA, Grogan TM, Miller TP, Frutiger Y, Chan WC, Gascoyne RD, Ott G, Muller-Hermelink HK, Staudt LM, Rimsza LM. Loss of MHC class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood 2006;108:311-318.
4. Rimsza LM, Farinha P, Fuchs DA, Masoudi H, Connors JM, Gascoyne RD. HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. Leuk Lymphoma 2007;48:542-546.
5. Roberts RA, Sabalos CM, LeBlanc ML, Martel RR, Frutiger YM, Unger JM, Botros IW, Rounseville MP, Seligmann BE, Miller TP, Grogan TM, Rimsza LM. Quantitative nuclease protection assay in paraffin embedded tissue replicates prognostic microarray gene expression in diffuse large B-cell lymphoma. Lab Invest 2007;87:979-997.PMID:17700362
6. Iqbal J, Greiner TC, Patel K, Dave BJ, Smith L, Ji J, Wright G, Sanger WG, Pickering DL, Jain S, Horsman DE, Shen Y, Fu K, Weisenburger DD, Hans CP, Campo E, Gascoyne RD, Rosenwald A, Jaffe ES, Delabie J, Rimsza L, Ott G, Muller-Hermelink HK, Connors JM, Vose JM, McKeithan T, Staudt LM, Chan WC;Leukemia/Lymphoma Molecular Profiling Project. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 2007;21:2332-2343.
7. Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, Ott G,  Muller-Hermelink HK, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Chan WC, Staudt LM. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008;319:1676-1679.
8. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD; International Peripheral T-Cell Lymphoma Project. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496-5504. PMID: 18385450. PMCID: PMC Journal – In Process
9. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Pro Natl Acad Sci USA. 2008;105:13520-13525. Doi:PMCID: PMC2533222
10. Rimsza LM, LeBlanc ML, Unger JM,  Miller TP, Grogan TM, Persky DO, Martel RR, Sabalos CM, Seligmann B, Braziel RM, Campo E, Rosenwald A, Connors JM, Sehn LH, Johnson N, Gascoyne RD. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008;112:3425-3433. doi: 10.1182/blood-2008-137372 PMID: 18840722. (free article).
11. Young KH, Leroy K, Moller MB, Colleoni GW, Sanchez-Beato M, Kerbauy FR, Haioun C, Eickhoff JC, Young AH, Gaulard P, Piris MA, Oberley TD, Rehrauer WM, Kahl BS, Malter JS, Campo E, Delabie J, Gascoyne RD, Rosewald A, Rimsza L, Huang J, Braziel RM, Jaffe ES, Wilson WH, Staudt LM, Vose JM, Chan WC, Weisenburger DD, Greiner TC. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 2008;112:3088-3098. doi: 10.1182/blood-2008-01-154013. Epub 2008 Jul 15. PMID: 18628487 PMCID: PMC2569165.
12. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-2323. PMID: 19038878
13. Rimsza LM, Chan WC, Gascoyne RD, Campo E, Jaffe ES, Staudt LM, Delabie J, Rosenwald A, Murphy SP. CIITA or RFX Coding Region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression. Haematologica 2009;94:596-598. doi: 10.3324/haematol.2008.00752. PMID: 19229048 PMCID: 2663627.
14. Cardesa-Salzmann TM, Colomo L, Gutierrez G, Chan WC, Weisenburger D, Climent F, González-Barca E, Mercadal S, Arenillas L, Serrano S, Tubbs R, Delabie J, Gascoyne RD, Connors JM, Mate JL, Rimsza L, Braziel R, Rosenwald A, Lenz G, Wright G, Jaffe ES, Staudt L, Jares P, López-Guillermo A, Campo E.  High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy.  Haematologica. 2011 Jul; 96(7): 996-1001. doi: 10.33324/haematol.2010.037408. Epub 2011 May 5. PMID: 21546504 PMCID: PMC3128218.
15. Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, Johnson NA, Zhao Y, Telenius A, Neriah SB, McPherson A, Meissner B, Okoye UC, Diepstra A, van den Berg A, Sun M, Leung G, Jones SJ, Connors JM, Huntsman DG, Savage KJ, Rimsza LM, Horsman DE, Stauds LM, Steidl U, Marra MA, Gascoyne RD.  MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011 Mar 17;471(7338):377-81. doi: 10.1038/nature09754. Epub 2011 Mar 2. PMID: 21368758. PMC Journal in Process.

Professional Information
Board Certifications: 

Dr. Rimsza is board certified by the American Board of Pathology in Anatomic and Clinical Pathology and subspecialty certified in Hematology.

Academic Information
Fellowship: 
University of New Mexico
Medical School: 
University of Arizona